“I strongly recommend Chen immigration law group for anyone who is seeking for immigration petition. The team is extremely professional and rigorous on every step during the case preparation, which minimized the chance of RFEs. I was not confident about my credentials but got my EB1B approved under their guidance.”

Case Summary:

Our client held a Doctor of Medicine in clinical medicine and her strong academic background in the field of cancer immunotherapy has laid the foundation for her current position as a research fellow in a well-acknowledged medicine college here in the United States. She hired North America Immigration Law Group to assemble an EB-1B (Outstanding Professors and Researchers) petition on her behalf. When we proceeded to evaluate her credentials, we reviewed the provided document and confirmed that we could guide her way to the EB1B case approval. Therefore, in her EB1B petition packet, we got the following details added:

• We noted that her work, the 9 peer-reviewed scientific articles, and 1 book chapter, all of which appeared in highly impacting journals, were cited by several well-reputed researchers 108 times. Her original research projects, impactful publications, and noteworthy citations demonstrate her impressive record, helping quantify her impact on cancer immunotherapy and closely related fields of study.
• We included the impressive 50 times our client judged the work of her fellow peers, signifying her great standing as a peer reviewer in the field.
• Also, we briefed the most important aspect in her petition i.e., her research focusing on the identification and characterization of novel immune checkpoints relevant to cancer risk and treatment. After thorough deliberation, we concluded that our client’s research addresses some of our nation’s most pressing issues in understanding the critical role that the immune system plays in cancer.
• To corroborate the fact that dozens of scholars have relied on her findings, we incorporated 4 recommendation letters that marked her as a highly influential researcher in the field. One of her recommenders stated that:

“[Client’s] research targets the underlying mechanisms associated with poor patient prognosis and a failure to respond to immunotherapy treatments. Perhaps of equal importance, her research uses the discovery of these mechanisms to identify novel therapeutic targets and develop new immunotherapies. For these reasons, her research is of great value to the many cancer patients who do not respond to immunotherapies, marking her work as especially valuable for U.S. healthcare.”

Her 15 years of cancer immunotherapy research demonstrates that she has extensive experience in her field, distinguishing her as a leader among her peers. Thus, our client successfully received her EB1B approval in just 9 days with our dedication and premium processing service upgrade. We would like to thank her for choosing us for managing her case, and we wish her the best in her future endeavors.